«The compelling results seen in this global study
provide unequivocal evidence supporting the clinical
utility of Oncotype DX to risk - stratify patients with early stage breast cancer, and indicate that the findings are generalizable to
everyday clinical practice,» said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medicine.